These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27042302)

  • 1. Prostaglandin D2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis.
    Cho C; Nguyen A; Bryant KJ; O'Neill SG; McNeil HP
    Immun Inflamm Dis; 2016 Mar; 4(1):64-9. PubMed ID: 27042302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of in vivo mast cell reactivity in patients with systemic mastocytosis.
    Gülen T; Möller Westerberg C; Lyberg K; Ekoff M; Kolmert J; Bood J; Öhd J; James A; Dahlén SE; Nilsson G; Dahlén B
    Clin Exp Allergy; 2017 Jul; 47(7):909-917. PubMed ID: 28258965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans.
    Song WL; Wang M; Ricciotti E; Fries S; Yu Y; Grosser T; Reilly M; Lawson JA; FitzGerald GA
    J Biol Chem; 2008 Jan; 283(2):1179-88. PubMed ID: 17993463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary prostaglandin metabolites as Duchenne muscular dystrophy progression markers.
    Takeshita E; Komaki H; Tachimori H; Miyoshi K; Yamamiya I; Shimizu-Motohashi Y; Ishiyama A; Saito T; Nakagawa E; Sugai K; Sasaki M
    Brain Dev; 2018 Nov; 40(10):918-925. PubMed ID: 30006121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome.
    Butterfield J; Weiler CR
    J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2533-2541. PubMed ID: 32142966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostaglandin D
    Maeda S; Nakamura T; Harada H; Tachibana Y; Aritake K; Shimosawa T; Yatomi Y; Murata T
    Sci Rep; 2017 Dec; 7(1):17687. PubMed ID: 29247205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extraction and measurement of urinary tetranor-PGDM in disposable diapers.
    Ito N; Nakamura T; Sakamoto N; Hayashi A; Murata T
    J Pharmacol Sci; 2021 Oct; 147(2):208-210. PubMed ID: 34384569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Monoclonal Antibody-Based EIA for Tetranor-PGDM which Reflects PGD
    Nagata N; Masuko S; Inoue R; Nakamura T; Aritake K; Murata T
    J Immunol Res; 2021; 2021():5591115. PubMed ID: 33997056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old.
    Nakagawa T; Takeuchi A; Kakiuchi R; Lee T; Yagi M; Awano H; Iijima K; Takeshima Y; Urade Y; Matsuo M
    Clin Chim Acta; 2013 Aug; 423():10-4. PubMed ID: 23603101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical and clinical validation of an LC-MS/MS method for urine leukotriene E4: A marker of systemic mastocytosis.
    Lueke AJ; Meeusen JW; Donato LJ; Gray AV; Butterfield JH; Saenger AK
    Clin Biochem; 2016 Sep; 49(13-14):979-82. PubMed ID: 26908217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.
    Woolley DE; Tetlow LC
    Arthritis Res; 2000; 2(1):65-74. PubMed ID: 11219391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease.
    Sperr WR; Jordan JH; Fiegl M; Escribano L; Bellas C; Dirnhofer S; Semper H; Simonitsch-Klupp I; Horny HP; Valent P
    Int Arch Allergy Immunol; 2002 Jun; 128(2):136-41. PubMed ID: 12065914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous and high-throughput quantitation of urinary tetranor PGDM and tetranor PGEM by online SPE-LC-MS/MS as inflammatory biomarkers.
    Zhang Y; Zhang G; Clarke PA; Huang JT; Takahashi E; Muirhead D; Steenwyk RC; Lin Z
    J Mass Spectrom; 2011 Jul; 46(7):705-11. PubMed ID: 21706677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary 11β-PGF2α and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders.
    Divekar R; Butterfield J
    Allergy; 2015 Oct; 70(10):1230-8. PubMed ID: 26095439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
    Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
    J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms.
    Alvarez-Twose I; González-de-Olano D; Sánchez-Muñoz L; Matito A; Jara-Acevedo M; Teodosio C; García-Montero A; Morgado JM; Orfao A; Escribano L
    Int Arch Allergy Immunol; 2012; 157(3):275-80. PubMed ID: 22042301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the role of PGD2 metabolites as markers of mast cell activation in asthma.
    O'Sullivan S
    Acta Physiol Scand Suppl; 1999 Apr; 644():1-74. PubMed ID: 10352758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2.
    Morrow JD; Guzzo C; Lazarus G; Oates JA; Roberts LJ
    J Invest Dermatol; 1995 Jun; 104(6):937-40. PubMed ID: 7769262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: diagnostic work-up of 38 patients.
    Van den Poel B; Kochuyt AM; Del Biondo E; Dewaele B; Lierman E; Tousseyn T; de Hertogh G; Vandenberghe P; Boeckx N
    Acta Clin Belg; 2017 Apr; 72(2):123-129. PubMed ID: 28262030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.